Rebecca E. Rudolph, MD, MPH; Thomas L. Vaughan, MD, MPH; Barry E. Storer, PhD; Rodger C. Haggitt, MD; Peter S. Rabinovitch, MD, PhD; Douglas S. Levine, MD; Brian J. Reid, MD, PhD
Acknowledgments: The authors thank Dr. Patricia Blount for her contributions to patient care in the Seattle Barrett's Esophagus Project, Ms. Carissa Sanchez for flow cytometric analyses, Mr. David Cowan and Ms. Janine Kikuchi for database management, Ms. Christine Karlsen and Ms. Sue Irvine for their contributions as patient care coordinators, and Ms. Tricia Christopherson for management of patient interviews.
Grant Support: By National Institutes of Health grants R01 CA61202 and R25 CA57734.
Requests for Single Reprints: Rebecca E. Rudolph, MD, MPH, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP-474, Box 19024, Seattle, WA 98109-1024.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, email@example.com.
Current Author Addresses: Drs. Rudolph, Vaughan, Storer, and Reid: Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP-474, Box 19024, Seattle, WA 98109-1024.
Dr. Haggitt: University of Washington Medical Center, Pathology, BB-210B, Box 356100, Seattle, WA 98195.
Dr. Rabinovitch: University of Washington, K-081 Health Sciences Pathology, Box 357470, Seattle, WA 98195.
Dr. Levine: AstraZeneca Pharmaceuticals, 725 Chesterbrook Boulevard, E-2C, Wayne, PA 19087-5677.
Author Contributions: Conception and design: R.E. Rudolph, T.L. Vaughan, D.S. Levine, B.J. Reid.
Analysis and interpretation of the data: R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.
Drafting of the article: R.E. Rudolph, T.L. Vaughan.
Critical revision of the article for important intellectual content: R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.
Final approval of the article: R.E. Rudolph, T.L. Vaughan, B.E. Storer, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.
Provision of study materials or patients: T.L. Vaughan, R.C. Haggitt, D.S. Levine, B.J. Reid.
Statistical expertise: R.E. Rudolph, T.L. Vaughan, B.E. Storer.
Obtaining of funding: T.L. Vaughan, P.S. Rabinovitch, B.J. Reid.
Administrative, technical, or logistic support: T.L. Vaughan, P.S. Rabinovitch, B.J. Reid.
Collection and assembly of data: R.E. Rudolph, T.L. Vaughan, R.C. Haggitt, P.S. Rabinovitch, D.S. Levine, B.J. Reid.
The increased risk for esophageal adenocarcinoma associated with long-segment (≥ 3 cm) Barrett esophagus is well recognized. Recent studies suggest that short-segment (<3 cm) Barrett esophagus is substantially more common; however, the risk for neoplastic progression in patients with this disorder is largely unknown.
To examine the relation between segment length and risk for aneuploidy and esophageal adenocarcinoma in patients with Barrett esophagus.
Prospective cohort study.
University medical center in Seattle, Washington.
309 patients with Barrett esophagus.
Patients were monitored for progression to aneuploidy and adenocarcinoma by repeated endoscopy with biopsy for an average of 3.8 years. Cox proportional-hazards analysis was used to calculate adjusted relative risks and 95% CIs.
After adjustment for histologic diagnosis at study entry, segment length was not related to risk for cancer in the full cohort (P > 0.2 for trend). When patients with high-grade dysplasia at baseline were excluded, however, a nonsignificant trend was observed; based on a linear model, a 5-cm difference in segment length was associated with a 1.7-fold (95% CI, 0.8-fold to 3.8-fold) increase in cancer risk. Among all eligible patients, a 5-cm difference in segment length was associated with a small increase in the risk for aneuploidy (relative risk, 1.4 [CI, 1.0 to 2.1]; P = 0.06 for trend). A similar trend was observed among patients without high-grade dysplasia at baseline.
The risk for esophageal adenocarcinoma in patients with short-segment Barrett esophagus was not substantially lower than that in patients with longer segments. Although our results suggest a small increase in risk for neoplastic progression with increasing segment length, additional follow-up is needed to determine whether the patterns of risk occurred by chance or represent true differences. Until more data are available, the frequency of endoscopic surveillance should be selected without regard to segment length.
Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, et al. Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus. Ann Intern Med. ;132:612–620. doi: 10.7326/0003-4819-132-8-200004180-00003
Download citation file:
Published: Ann Intern Med. 2000;132(8):612-620.
Esophageal Disorders, Gastroenterology/Hepatology, Hematology/Oncology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use